142 related articles for article (PubMed ID: 37713930)
21. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
22. Progastrin: An Overview of Its Crucial Role in the Tumorigenesis of Gastrointestinal Cancers.
Fioretzaki R; Sarantis P; Charalampakis N; Christofidis K; Mylonakis A; Koustas E; Karamouzis MV; Sakellariou S; Schizas D
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672239
[TBL] [Abstract][Full Text] [Related]
23. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
[TBL] [Abstract][Full Text] [Related]
24. Relationship between tumor cell infiltration and 5-aminolevulinic acid fluorescence signals after resection of MR-enhancing lesions and its prognostic significance in glioblastoma.
Kim J-; Jung T-; Jung S; Kim I-; Jang W-; Moon K-; Kim S-; Kim J-; Lee K-
Clin Transl Oncol; 2021 Mar; 23(3):459-467. PubMed ID: 32617871
[TBL] [Abstract][Full Text] [Related]
25. Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma.
Seyve A; Lozano-Sanchez F; Thomas A; Mathon B; Tran S; Mokhtari K; Giry M; Marie Y; Capelle L; Peyre M; Carpentier A; Feuvret L; Sanson M; Hoang-Xuan K; Honnorat J; Delattre JY; Ducray F; Idbaih A
Clin Neurol Neurosurg; 2020 Sep; 196():106006. PubMed ID: 32554237
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of follow-up treatment regimens for colorectal cancer liver metastases without objective response to neoadjuvant chemotherapy: direct surgery or surgery after second-line chemotherapy].
Lyu XY; Bi XY; Zhao H; Chen QC; Luo ZW; Zhang BL; Zhang XS; Cai JQ
Zhonghua Wai Ke Za Zhi; 2022 May; 60(5):454-460. PubMed ID: 35359087
[No Abstract] [Full Text] [Related]
27. The anesthetist's choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients.
Schmoch T; Jungk C; Bruckner T; Haag S; Zweckberger K; von Deimling A; Brenner T; Unterberg A; Weigand MA; Uhle F; Herold-Mende C
Neurosurg Rev; 2021 Oct; 44(5):2707-2715. PubMed ID: 33354749
[TBL] [Abstract][Full Text] [Related]
28. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.
McNamara MG; Lwin Z; Jiang H; Templeton AJ; Zadeh G; Bernstein M; Chung C; Millar BA; Laperriere N; Mason WP
J Neurooncol; 2014 Mar; 117(1):147-52. PubMed ID: 24469854
[TBL] [Abstract][Full Text] [Related]
29. Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study.
Pallud J; Huberfeld G; Dezamis E; Peeters S; Moiraghi A; Gavaret M; Guinard E; Dhermain F; Varlet P; Oppenheim C; Chrétien F; Roux A; Zanello M
Neurology; 2022 Jan; 98(2):e125-e140. PubMed ID: 34675100
[TBL] [Abstract][Full Text] [Related]
30. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
31. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K
Oncology; 2019; 97(5):255-263. PubMed ID: 31288238
[TBL] [Abstract][Full Text] [Related]
32. Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma.
An G; Ahn S; Park JS; Jeun SS; Hong YK
J Cancer Res Clin Oncol; 2021 Mar; 147(3):901-909. PubMed ID: 32929611
[TBL] [Abstract][Full Text] [Related]
33. Intraoperative serum lactate is not a predictor of survival after glioblastoma surgery.
Cata JP; Bhavsar S; Hagan KB; Arunkumar R; Grasu R; Dang A; Carlson R; Arnold B; Popat K; Rao G; Potylchansky Y; Lipski I; Ratty S; Nguyen AT; McHugh T; Feng L; Rahlfs TF
J Clin Neurosci; 2017 Sep; 43():224-228. PubMed ID: 28601568
[TBL] [Abstract][Full Text] [Related]
34. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
35. [Factor analysis of cerebrospinal fluid spread in glioblastoma].
Huang J; Li MX; Ma ML; Ren XH; Cui Y; Lin S
Zhonghua Wai Ke Za Zhi; 2020 Jun; 58(6):469-474. PubMed ID: 32498488
[No Abstract] [Full Text] [Related]
36. Body mass index as an independent prognostic factor in glioblastoma.
Valente Aguiar P; Carvalho B; Vaz R; Linhares P
Cancer Causes Control; 2021 Apr; 32(4):327-336. PubMed ID: 33447892
[TBL] [Abstract][Full Text] [Related]
37. The Assessment of Clinical Outcomes and Prognostic Factors in Glioblastoma Patients.
Demircan NV; Erpolat OP; Guzel C; Senturk E; Bora H; Karahacioglu E
Turk Neurosurg; 2023; 33(5):870-886. PubMed ID: 37528719
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
[TBL] [Abstract][Full Text] [Related]
39. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
[TBL] [Abstract][Full Text] [Related]
40. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
